Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APGE |
---|---|---|
09:32 ET | 3206 | 58.13 |
09:34 ET | 700 | 59.0599 |
09:36 ET | 1335 | 57.915 |
09:56 ET | 100 | 57.8 |
09:57 ET | 1665 | 57.76 |
09:59 ET | 300 | 57.48 |
10:01 ET | 665 | 58.11 |
10:03 ET | 300 | 58.21 |
10:06 ET | 500 | 58.14 |
10:08 ET | 500 | 58.07 |
10:10 ET | 300 | 58.235 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Apogee Therapeutics Inc | 3.4B | -25.9x | --- |
Dyne Therapeutics Inc | 3.5B | -9.7x | --- |
MoonLake Immunotherapeutics | 3.3B | -56.3x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Merus NV | 3.2B | -16.5x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -25.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.